Identification of a New Exosite Involved in Catalytic Turnover by the Streptokinase-Plasmin Activator Complex during Human Plasminogen Activation

Rachna Anjea, Manish Datt, Balwinder Singh, Shekhar Kumar, and Girish Sahni

From the Department of Molecular Biology and Protein Engineering, The Institute of Microbial Technology (CSIR), Sector 39-A, Chandigarh 160036, India

With the goal of identifying hitherto unknown surface exosites of streptokinase involved in substrate human plasminogen recognition and catalytic turnover, synthetic peptides encompassing the 170 loop (CQFTPLNPDDDFRPGK-DTKLLC) in the β-domain were tested for selective inhibition of substrate human plasminogen activation by the streptokinase-plasmin activator complex. Although a disulfide-constrained peptide exhibited strong inhibition, a linear peptide with the same sequence, or a disulfide-constrained variant with a single lysine to alanine mutation showed significantly reduced capabilities of inhibition. Alanine-scanning mutagenesis of the 170 loop of the β-domain of streptokinase was then performed to elucidate its importance in streptokinase-mediated plasminogen activation. Some of the 170 loop mutants showed a remarkable decline in $k_{cat}$ without any alteration in apparent substrate affinity ($K_m$) as compared with wild-type streptokinase and identified the importance of Lys$^{180}$ as well as Pro$^{177}$ in the functioning of this loop. Remarkably, these mutants were able to generate amidolytic activity and non-proteolytic activation in “partner” plasminogen as wild-type streptokinase. Moreover, cofactor activities of the 170 loop mutants, pre-complexed with plasmin against microplasmin as the substrate showed a similar pattern of decline in $k_{cat}$ as that observed in the case of full-length plasminogen, with no concomitant change in $K_m$. These results strongly suggest that the 170 loop of the β-domain of streptokinase is important for catalysis by the streptokinase-plasminogen activator complex, particularly in catalytic processing/turnover of substrate, although it does not seem to contribute significantly toward enzyme-substrate affinity per se.

Plasminogen activation, a key event in physiological fibrinolysis, is a widely employed therapeutic means to rapidly alleviate circulatory disorders that arise due to obstruction of blood flow by pathological thrombi (1). Streptokinase (SK), a bacteria-derived thrombolytic protein, activates plasminogen by forming a high affinity stoichiometric complex with “partner” plasminogen, which, after a conformational activation step, acquires the capability to selectively cleave the Arg$^{561}$-Val$^{562}$ scissile peptide bond in “substrate” plasminogen, thereby converting the latter into HPN, plasmin (2, 3). Elegant equilibrium binding and kinetic studies directed toward resolving the steps involved in the phenomenon of conformational activation of HPG by SK demonstrate a relatively rapid formation of a SK-HPG* complex, a “conformationally activated” state, due to the generation of a nonproteolytically activated active center, which is also amidolytically active (4). This conformationally activated SK-HPG* complex can then recruit a substrate molecule of HPG (3, 9) and proteolytically activate it, likely through inter-molecular proteolytic scission, into HPN. In addition, the HPG moiety in the SK-HPG* activator complex can exchange with free HPN preferentially (because the latter has been shown to have nearly three orders higher affinity for SK) to form a SK-HPN complex (the fully mature activator complex) possessing strong HPG activation capability (5, 7) (Fig. 1). One of the fascinating aspects of HPG activation reaction is the molecular mechanisms whereby the binding of SK to HPN modulates the substrate specificity of the latter (with, essentially, a trypsin-like broad specificity), virtually re-programming it to a very high degree of preference for the Arg$^{561}$, Val$^{562}$, the scissile peptide bond of substrate HPG that leads to the HPG proteolytic activation (5–8). The crystal structure of SK complexed with μPN (the isolated catalytic domain of HPN), with which SK forms a tight binary complex as it does with full-length HPG, reveals that the domains of SK form a “three-sided crater,” with the μPN situated at the bottom of a valley into which the substrate’s catalytic domain, bearing the “target” scissile peptide bond to be cleaved, can potentially dock (9). Besides the crystal structure, the crucial role of long range protein-protein interactions between the enzyme (SK-plasmin) and its macromolecular substrate HPG have become increasingly clear through domain truncation studies on both SK and HPG, and various other approaches (10–14). Interestingly, the crystal structure of SK-μPN reveals that each of the three SK domains contains a number of both defined and undefined loops, some of which are positioned to potentially bind with docked substrate plasminogen (9). An epitope in SK, the so-called 88–97 loop of streptokinase α-domain, has been identified recently (12) as being important in both 1:1 as well as ternary, enzyme-substrate interactions. However, its overall contribution toward plasminogen activation cannot be de-
Mechanism of Streptokinase Action

**Pathway I, Conformational activation pathway**

\[ \text{SK + HPG} \xrightarrow{\text{Cofactor + Zymogen}} \text{SK.HPG} \xrightarrow{\text{nonproteolytically active HPG}} \text{SK.HPG* + HPG} \xrightarrow{\text{nonproteolytically active HPG recruits free HPG}} \text{SK.HPG*.HPG} \xrightarrow{\text{nonproteolytically active HPG activates free HPG to HPN}} \text{SK.HPG* + HPN} \]

**Pathway II, Direct proteolytic activation pathway**

\[ \text{SK + HPN} \xrightarrow{\text{Cofactor + Enzyme}} \text{Enzyme complex} \xrightarrow{\text{Enzyme complex recruits free HPG}} \text{SK.HPN+HPG} \xrightarrow{\text{SK.HPN activator complex proteolytically activates HPG}} \text{SK.HPN activator complex} \xrightarrow{\text{cofactor, Enzyme + Product}} \text{SK.HPN + HPN} \]

**FIGURE 1. Currently understood mechanism of plasminogen activation by streptokinase.** SK forms an equimolar complex with HPG (Pathway I) that leads to the generation of an active center in the complex (SK-HPG*) without cleavage of scissile peptide bond in the partner HPG. This “virgin complex” then recruits free HPG as substrate and converts the latter into HPN. The HPN so formed rapidly exchanges with the HPG* from SK-HPG* complex due to its multifold higher affinity for SK in comparison to HPG. Alternatively, the SK can directly combine with the HPN to make SK-HPN activator complex (Pathway II). The activator complex then catalytically acts on substrate HPG molecules and converts them into HPN.

more than an order of drop in \( k_{\text{cat}} \) even though substrate affinity of the mutants, as well as their capability to engender the non-proteolytic activation in partner plasminogen, as tested through the activation of scissile-peptide bond mutant of microplasminogen (μPG R561A) remains unaltered. Thus, the present study identifies a new exosite in SK that is important in the activation of HPG.

**EXPERIMENTAL PROCEDURES**

**Materials**—Glutammine was either purchased from Roche Diagnostics GmbH, Germany, or purified from human plasma by affinity chromatography (17). The T7 RNA polymerase-promoter-based expression vector, pET 23(d), and Escherichia coli strain BL21 (DE3) were products of Novagen Inc. (Madison, WI). Thermostable DNA polymerase (pfu Turbo™) was obtained from Stratagene Inc. (La Jolla, CA). Oligonucleotide primers were supplied by Biobasic Inc., Canada. Phenyl-agarose 6XL was procured from Prometic Biosciences Ltd., UK, and DEAE-Sepharose (fast-flow) from Amersham Biosciences. Urokinase, e-aminocaproic acid, sodium cyanoborohydride, and L-lysine were purchased from Sigma. All other reagents used were of the highest analytical grade available.

**Peptide Synthesis**—Custom synthesis of the peptides derived from the 170 loop primary structure, namely CQFTPLNPDDDFRPGLKDTKLLC, or its mutated sequence, namely CQFTP-LNPDDDFRPGLADTKLLC, was carried out using standard Fmoc (N-(9-fluorenylmethoxycarbonyl)-based solid-phase peptide chemistry on an automated peptide synthesizer model PS3 by M/s USV, Mumbai, India. After synthesis and cleavage by standard procedures, the peptides were purified on reverse transcription-high-performance liquid chromatography and disulfide-constrained peptide, were cyclized by \( H_2O_2 \) treatment. Linear peptides were N-terminally acetylated and their C-terminal amidated.

**Design and Construction of Various SK Loop Mutants**—The SK gene from *Streptococcus equisimilis* H46A strain, a type C streptococcus, was earlier cloned in pET 23d vector (11), and this construct was used to prepare all substitution mutants. The substitution point-mutations of the 170 loop of the β-domain of SK were prepared by using a QuikChange® mutagenesis kit obtained from Stratagene Inc., which involves usage of two complementary primers having the desired mutation at the center (see supplemental Table S1 for a list of the primers designed for the various mutants).

**Expression and Purification of wtSK/SK Loop Mutants**—The wtSK and 170 loop mutants cloned in pET 23d were expressed intracellularly in *E. coli* BL21 (DE3) cells as inclusion bodies under the control of the T7 phage RNA polymerase promoter.
after induction with isopropyl-1-thio-β-D-galactopyranoside, and purified as described (11).

Preparation of HPN—Plasmin (HPN), the active form of HPG, was prepared by digesting Glu-HPG with urokinase covalently immobilized on agarose beads using a ratio of 300 Plough units/mg HPG in 50 mM Tris-Cl, pH 8.0, 25% glycerol, and 25 mM L-lysine at 22 °C for 10 h (11).

Preparation of μPG—μPG, the catalytic domain of plasminogen (residues Lys530–Asn790) made devoid of all five kringle domains, was prepared by cleavage of HPG by HPN under alkaline conditions (0.1 M glycine/NaOH buffer, pH 10.5) at 25 °C (18). Recombinant μPG and its scissile bond-perturbed mutant, R561A, were expressed and purified as described earlier (19).

Assays for Determining Inhibition of HPG Activator Activity of Pre-formed wtSK/HPN or Mutant SK-HPN Complex by Peptides Comprising 170 Loop Amino Acid Sequence/Mutated 170 Loop Sequence—The SK-HPN activator complex was formed by preincubating equimolar concentrations (0.5 μM each) of SK and HPN in 50 mM Tris-Cl, pH 7.5, and 0.5% bovine serum albumin at 22 °C for 1 min (20). This enzyme complex, at a final concentration of 5 nM, was added to reaction mixes already containing various concentrations of individual peptides (0–500 μM) in assay buffer containing 50 mM Tris-Cl, pH 7.5, and 100 mM NaCl preincubated with 0.05 μM of HPG for 10 min. The generation of plasminogen activator activity was measured spectrophotometrically at 405 nm by recording the increase in rate of release of p-nitroanilide from the chromogenic substrate by the human plasmin generated as a result of HPG activation for a period of 10 min at 22 °C. A control reaction contained all components except the test peptide. The specific activity at each concentration of inhibitory peptide was calculated by obtaining the slopes of the activation progress curves as change in absorbance/t2. The extent of inhibition by different concentrations of the given peptide was determined and expressed in percentage relative to control reactions (taken as 100%) conducted in the absence of peptide.

Assays for Studying the Activation of HPG by wtSK and SK Mutants—A one-stage colorimetric assay method, was used to measure the kinetics of HPG activation by wtSK or its mutants (21). The change in absorbance at 405 nm was then measured as a function of time (t) in a Molecular Devices Versamax microplate reader at 22 °C. The activator activities were obtained from the slopes of the activation progress curves as change in absorbance/t2 (21).

N-terminal Methionine Removal from wtSK/170 Loop Mutants—The N-terminal methionine was removed from wtSK and 170 loop mutants using methionine aminopeptidase (MetAP) enzyme by a procedure, as described previously (22). The extent of removal of the N-terminal methionine was determined by N-terminal sequence analysis on Applied Biosystems sequencer, Model 491A, and also through quantitative amino acid composition analysis.

Esterolytic Activation of Equimolar HPG-SK/170 Loop Mutant Complex—To monitor the active site formation 7 μM HPG was added to an assay cuvette containing 7.5 μM wtSK/mutant, 100 μM NPGB, and 10 mM sodium phosphate buffer, pH 7.5. The “burst” of p-nitrophenol release due to acylation of active center was monitored at 410 nm as a function of time at 22 °C (2, 23, 24).

Amidolytic Activation by Equimolar wtSK/SK Loop Mutant of R561A μPG Mutant—R561A μPG mutant (final concentration, 5.0 μM) was incubated with 5.5 μM wtSK or a mutant SK, in 0.5% bovine serum albumin, 50 mM Tris-Cl buffer, pH 7.5. The time course of amidolytic activity generation was determined after transferring an aliquot of the complex to a 100-μl reaction well containing assay buffer, 50 mM Tris-Cl, pH 7.5, 100 mM NaCl along with 1 mM Chromozym®-PL (the transfer time (including initial complexation was 30 s). Final concentrations of the complex in the amidolytic assay reaction was 10 nM. The change in absorbance at 405 nm was monitored spectrophotometrically as a function of time (19).

Determination of Steady-state Kinetic Constants for HPG/μPG Activator Activity of wtSK/SK Loop Mutants—The kinetics of HPG/μPG activation by HPNwtSK/SK-loop mutant complexes was measured by transferring suitable aliquots (usually, so as to attain a 0.5 mM final concentration in the assay mix) of preformed HPNwtSK/SK loop mutant complexes to the reaction wells containing varying concentrations of substrate HPG/μPG in assay buffer (50 mM Tris-Cl buffer, pH 7.5, and 100 mM NaCl) also containing 0.5 mM chromogenic substrate Chromozym®-PL. The generation of activator activity was monitored at 22 °C at 405 nm as before. The kinetic parameters for HPG/μPG activation were then calculated from Michaelis–Menten (ν versus S) and inverse (1/ν versus 1/S) Lineweaver-Burk plots (20).

Kinetic Analysis of Protein-Protein Interactions by Surface Plasmon Resonance—Ternary Interaction Analysis—A surface plasmon resonance-based biosensor was also used to measure the rate and equilibrium dissociation constants describing interactions between soluble analytes (HPG and μPG) and wtSK/SK loop mutants complexed with immobilized HPG, a situation simulating substrate binding to binary complex and hereafter referred to as ternary interaction as described previously (14). Experiments were performed at 25 °C in HBS “running buffer” (30 mM Hepes, pH 7.4, 135 mM NaCl, and 1 mM EDTA) supplemented with 0.05% Tween 20 and 5 mM NPGB. The NPGB was included to prevent plasmin-mediated proteolysis (14) (see supplemental Figs. S4 and S5 for binding sensorgrams). After subtracting the nonspecific response the association and dissociation curves according to a 1:1 binding model, using BIACORE 3000 evaluation software.

RESULTS AND DISCUSSION

Selective Inhibition of the Activator Activity of the Preformed wtSK-HPN Enzyme Complex by Peptides Comprising Residues 165–185 of the Primary Structure of SK—With the objective to explore the possible role of the 170 loop of SK in plasminogen activation, a set of peptides was synthesized corresponding to residues Pro165 to Leu185 (each containing 23 residues), including unconstrained, linear, and peptides constrained at the N and C termini through an intramolecular disulfide bond (25) after cysteine additions at both ends (see “Experimental
Selective inhibition of substrate HPG activation ability of wtSK-HPN activator complex by 170 loop peptide mimotopes. Aliquots of preformed SK-HPN complex (5 nM) were added to HPG (0.05 μM) in assay buffer containing various concentrations of the 170 loop sequence peptides (0–500 μM). Residual percent activity in the presence of either linear, unconstrained 170 loop peptide (open circles), wild-type cyclic 170 loop peptide (solid squares), linear K180A peptide (solid circles), or the disulfide constrained cyclic K180A peptide (solid diamonds), was calculated from the rates of plasmin generated in the presence of peptide compared with that of activation reaction (taken as 100%) where no peptide was added (see “Experimental Procedures” for details). The control reactions where either plasmin inhibition (in the absence of SK) was tested in the presence of peptides are also depicted (upward triangles), or where possible inhibition of SK-HPN activator complex in the absence of substrate plasminogen (downward triangles) are also depicted.

Remarkably, Peptide 2 (wild-type 170 loop sequence constrained through a disulfide bond) inhibited the activation of substrate HPG in a concentration-dependent manner in the low micromolar range of concentration, whereas the linear peptide, i.e. Peptide 1, could not inhibit substrate HPG activation significantly compared with uninhibited controls (see Fig. 2 and supplemental Fig. S1 for actual progress curves showing direct inhibition by the constrained peptide). This observation indicated that the linear, 170 loop peptide probably remains in an extended conformation incapable of competing with SK-HPN for its substrate interactions, whereas the cyclic peptide adopts a conformation that mimics the 170 loop epitope in the native structure of SK. Apart from testing for inhibition of the preformed wtSK-HPN enzyme complex, the two peptides were tested for their ability to inhibit amidolytic activity of HPG, on the one hand, and also the amidolytic activity of SK-HPN complex, on the other. In both cases, no observable inhibition could be seen in the amidolytic activity of free HPG as well as wtSK-HPN complex, which suggests that this 170 loop peptide selectively interferes in the interaction of the activator enzyme with substrate HPG, and thereby competitively inhibits its activation.

Construction, Purification, and Functional Characterization of Alanine Substitution Mutants of the 170 Loop of the β-Domain of SK—The sequence of residues 170–181 of SK, which comprises the 170 loop in the β-domain of this tri-domain protein, consists of a stretch containing several positively and negatively charged residues (16, 25). To further explore the possible role of this loop in SK-mediated plasminogen activation, and also to identify its important residues if the loop were indeed important in HPG activation, alanine substitution mutations were introduced into the loop in the full-length SK expressed in E. coli BL21 (DE3) cells as inclusion bodies and purified to near-homogeneity (see “Experimental Procedures” for details). Far-UV CD spectra of the purified 170 loop mutants (data not shown) showed a close resemblance with that of the wtSK, which was suggestive of the absence of any major structural impairment caused by the loop mutations.

The mutants were then characterized for their ability to activate HPG by a single-stage continuous spectrophotometric assay that measures the overall HPG activator activity using catalytic amounts of SK and a large excess of HPG (28). The relative slopes of the progress curves so obtained (see Fig. 3, which shows the time course of plasmin generation by some of the alanine mutants compared with that of wtSK) clearly indicate that the alanine substitution mutants of 170 loop exhibited varied extents of reduction in their HPG activation capabilities. Of all the single-site substitution mutants tested, we observed that K180A exhibited the most compromised plasminogen activator activity, roughly of an order of magnitude less compared with wild-type SK. This was followed by P177A and R176A, carrying substitutions toward the central region of the loop. However, some mutants (D172A, D173A, and D174A) showed, at most, only a minor decrease in activity compared with wtSK.

Because alanine substitution at position 180 in the full-length protein led to reduced plasminogen activation, it was of interest to perform direct inhibition assays with wtSK-HPN or mutant SK-HPN, as before, using the synthetic peptide approach. Using 170 loop wild-type peptide, both linear as well as cyclic, we checked for a possible inhibition of the mutant K180A-HPN enzyme complex, but none of these exhibited any significant inhibition at or near the concentrations seen to be inhibitory.
Mechanism of Streptokinase Action

with wtSK-HPN (data not shown). This result suggests that the 170 loop sequence derived (wild-type) peptide, which likely mimics the specific conformation of the epitope present in the 170 loop of β-domain in streptokinase, loses its recognition (and, hence, capability for inhibition) once SK is mutated at the 180 position. To further explore the importance of this lysine to alanine substitution, linear as well as cyclic synthetic peptides, as before, carrying the alanine substitution at lysine 180 position were used to test for inhibition of wtSK-HPN enzyme complex in the HPG activation assays (Fig. 2; see also supplemental Fig. S1 for actual progress curves showing no inhibition by the mutated constrained peptide). From these results, it is apparent that the mutated constrained peptide had lost its ability for inhibition. Thus, overall, the results strongly support the conclusion that the 170 loop sequence represents a “hot spot” involved in substrate activation by SK-HPN.

Interaction of the 170 Loop Mutants of SK with Partner HPG/μPG—Because some of the single substitution mutants of the 170 loop exhibited significant reduction in their plasminogen activator capability, as monitored through single-stage assays, it was of interest to explore the underlying cause of this decline in activity, i.e. whether it was the amidolytic/zymogen activation step, which operates through Pathway I (schematically presented in Fig. 1) wherein 1:1 complexation of HPG with SK and formation of the SK-HPG* activator complex occurs, was affected, or a step subsequent to this, in Pathway II, namely the interaction of substrate HPG with the fully mature mutant SK-HPN complex. To address this issue, the ability of 170 loop mutants to generate the active site in HPG upon 1:1 complexation was examined through the well known reaction with the active site acylating agent, which is characterized by a rapid acylation of the active site in SK-HPG* marked by a burst of color liberation (24). This enables one to detect the formation of the activator complex even in the absence of proteolytic scission in the zymogen. Because amidolytic/esterolytic activation of HPG through Pathway I requires the presence of an intact N-terminal Ile (Ile1) in SK (19, 29, 30), it may be mentioned that HPG through Pathway I requires the presence of an intact constraining group in the zymogen. Because amidolytic/esterolytic activation of the activator complex even in the absence of proteolytic scission in the zymogen activator capability, as monitored through single-stage assays, it was of interest to explore the underlying cause of this decline in activity, i.e. whether it was the amidolytic/zymogen activation step, which operates through Pathway I (schematically presented in Fig. 1) wherein 1:1 complexation of HPG with SK and formation of the SK-HPG* activator complex occurs, was affected, or a step subsequent to this, in Pathway II, namely the interaction of substrate HPG with the fully mature mutant SK-HPN complex. To address this issue, the ability of 170 loop mutants to generate the active site in HPG upon 1:1 complexation was examined through the well known reaction with the active site acylating agent, which is characterized by a rapid acylation of the active site in SK-HPG* marked by a burst of color liberation (24). This enables one to detect the formation of the activator complex even in the absence of proteolytic scission in the zymogen. Because amidolytic/esterolytic activation of HPG through Pathway I requires the presence of an intact N-terminal Ile (Ile1) in SK (19, 29, 30), it may be mentioned that HPG through Pathway I requires the presence of an intact constraining group in the zymogen. Because amidolytic/esterolytic activation of the activator complex even in the absence of proteolytic scission in the zymogen activator capability, as monitored through single-stage assays, it was of interest to explore the underlying cause of this decline in activity, i.e. whether it was the amidolytic/zymogen activation step, which operates through Pathway I (schematically presented in Fig. 1) wherein 1:1 complexation of HPG with SK and formation of the SK-HPG* activator complex occurs, was affected, or a step subsequent to this, in Pathway II, namely the interaction of substrate HPG with the fully mature mutant SK-HPN complex. To address this issue, the ability of 170 loop mutants to generate the active site in HPG upon 1:1 complexation was examined through the well known reaction with the active site acylating agent, which is characterized by a rapid acylation of the active site in SK-HPG* marked by a burst of color liberation (24). This enables one to detect the formation of the activator complex even in the absence of proteolytic scission in the zymogen. Because amidolytic/esterolytic activation of HPG through Pathway I requires the presence of an intact N-terminal Ile (Ile1) in SK (19, 29, 30), it may be mentioned that HPG through Pathway I requires the presence of an intact constraining group in the zymogen. Because amidolytic/esterolytic activation of the activator complex even in the absence of proteolytic scission in the zymogen activator capability, as monitored through single-stage assays, it was of interest to explore the underlying cause of this decline in activity, i.e. whether it was the amidolytic/zymogen activation step, which operates through Pathway I (schematically presented in Fig. 1) wherein 1:1 complexation of HPG with SK and formation of the SK-HPG* activator complex occurs, was affected, or a step subsequent to this, in Pathway II, namely the interaction of substrate HPG with the fully mature mutant SK-HPN complex. To address this issue, the ability of 170 loop mutants to generate the active site in HPG upon 1:1 complexation was examined through the well known reaction with the active site acylating agent, which is characterized by a rapid acylation of the active site in SK-HPG* marked by a burst of color liberation (24). This enables one to detect the formation of the activator complex even in the absence of proteolytic scission in the zymogen. Because amidolytic/esterolytic activation of HPG through Pathway I requires the presence of an intact N-terminal Ile (Ile1) in SK (19, 29, 30), it may be mentioned that the E. coli-derived, purified wtSK and the mutants had nearly 0.6 (14) mol of Ile per mole of protein as their N-terminal residue, which indicates a fairly high level of intracellular processing of the proteins by intrinsic E. coli fMet aminopeptidase (31). Subsequent methionine depletion of purified wtSK and K180A mutant under in vitro conditions was therefore carried out with MetAP (see “Experimental Procedures” for details). This resulted in further reduction of fMet to <0.1 mol/mol in both proteins. When these samples were reacted with NPGB, a nearly 2-fold jump in the extent of absorbance change for both wtSK and K180A mutant was observed (data not shown). The results presented in (Fig. 4) clearly show comparable acylation by the 170 loop mutant (K180A) and that of wtSK, which is in consonance with the results obtained through active site activation of HPG, shown in supplemental Fig. S2. Closely similar results were obtained with two other mutants tested, namely SK K180G and SK K180D (data not shown).

Likewise, the induction of a native-like complexation and opening of the active site in partner moiety through the use of the scissile peptide bond-mutated μPG (R561A), which does not transform to its plasminogen form, is also a test for Pathway I capability (19, 29). Past studies have shown that the R561A mutant of μPG can be activated by SK without being converted to μPN, and hence, can be utilized to rigorously test whether Pathway I capability is intact or compromised in a given SK mutant (19, 29). Accordingly, equimolar complexes of native SK or K180A with μPG R561A were tested (see “Experimental Procedures”) in a continuous spectrophotometric assay for amidolysis (Fig. 5). The results obtained clearly show the generation of nearly equivalent amidolytic activity upon addition of either K180A mutant or wtSK to R561A μPG mutant at 37°C (Fig. 5).

From these experiments, we can conclude that both wtSK as well as the 170 loop mutants have equivalent capability to generate amidolytic/amidolytic activity (NPGB hydrolysis) in partner HPG (see supplemental Fig. S2 for amidolytic activity generation in HPG), and therefore, the primary “functional lesion” due to 170 loop mutagenesis does not impair active site creation.
Interestingly, a nearly 10-fold drop in state kinetic parameters (28). The results are shown in Table 1.

The kinetic parameters for substrate HPG activation were determined at 22 °C with the chromogenic substrate in 50 mM Tris-Cl buffer, pH 7.5, 100 mM NaCl as described under “Experimental Procedures.” The data represent the mean of three independent determinations.

| Activator species | $K_m$ (μM) | $k_{cat}$ (min$^{-1}$) | $k_{cat}/K_m$ (min$^{-1}$ μM)$^{-1}$ |
|-------------------|------------|------------------------|-----------------------------------|
| wtSK              | 0.40 ± 0.05| 7.50 ± 0.3             | 19.00                             |
| P171A             | 0.40 ± 0.04| 7.00 ± 0.5             | 17.50                             |
| D172A             | 0.50 ± 0.06| 7.00 ± 0.5             | 14.0                              |
| D173A             | 0.50 ± 0.08| 7.10 ± 0.4             | 14.2                              |
| D174A             | 0.50 ± 0.07| 6.50 ± 0.3             | 13.0                              |
| R176A             | 0.60 ± 0.06| 4.50 ± 0.4             | 7.5                               |
| P177A             | 0.45 ± 0.08| 0.80 ± 0.03             | 1.7                               |
| K180A             | 0.50 ± 0.03| 0.70 ± 0.01             | 1.40                              |
| D181A             | 0.55 ± 0.06| 3.30 ± 0.34             | 6.3                               |
| K180D             | 0.50 ± 0.06| 0.20 ± 0.06             | 0.4                               |
| K180G             | 0.60 ± 0.05| 0.60 ± 0.04             | 1.0                               |
| K180R             | 0.50 ± 0.07| 3.20 ± 0.50             | 6.4                               |
| 177 pro del       | 0.60 ± 0.05| 0.80 ± 0.06             | 1.3                               |
| R176A/K180A       | 0.60 ± 0.08| 0.70 ± 0.15             | 1.2                               |
| R176A/D181A       | 0.40 ± 0.07| 4.00 ± 0.45             | 10                                |
| P177A/K180A       | 0.50 ± 0.07| 0.70 ± 0.02             | 1.4                               |
| K180A/D181A       | 0.50 ± 0.06| 0.80 ± 0.03             | 1.4                               |
| R176A/K180A/D181A | 0.60 ± 0.08| 0.40 ± 0.04             | 0.6                               |

by SK in partner HPG moieties during the formation of a fully mature activator complex. This observation supports the conclusion that the reduced HPG activator capability observed in the mutant SK-HPN complexes arises from compromised enzyme-substrate interactions, rather than catalytic events related to 1:1 complexation of SK with HPG, and the maturation of the latter to the SK-HPN state.

**Steady-state Kinetics of Plasminogen Activation by Equimolar Complexes of the 170 Loop Mutants with Plasmin Shows Selective Decline in Their Turnover Rates with No Concomitant Change in Enzyme-Substrate Affinity**—To identify the underlying catalytic step that was affected in the various single substitution mutants of the 170 loop, steady-state kinetic studies were performed using a two-stage assay in which the Pathway II capability, i.e. the ability of the SK-HPN complex to act on substrate HPG is measured selectively (32, 33). Equimolar complexes of wtSK, or that of the individual 170 loop mutants, with HPG were first made, and their catalytic amounts were then employed as the enzyme complex for the activation of varying substrate HPG concentrations. The progress of each reaction was followed spectrophotometrically so as to obtain the steady-state kinetic parameters (28). The results are shown in Table 1. Interestingly, a nearly 10-fold drop in $k_{cat}$ was observed in the case of the K180A mutant without any significant change in the apparent affinity ($K_m$) for substrate HPG (see supplemental Fig. S3 for the plots). It may be mentioned here that the plasminogen activator (specific) activity of the 170 loop mutant K180A remained compromised even when the mutant enzyme complex used to activate substrate HPG was at concentrations up to nearly 1000-fold higher than the concentrations usually employed in these assays (data not shown). If indeed the 1:1 affinity of the 170 loop mutants were compromised (and their low activity was a result of a non-optimal association of the mutant with plasmin), the specific activity obtained at say, the 100- and 1000-fold higher concentrations of the enzyme would have tended to become like that of wtSK. In contrast to K180A, the mutant P171A, and the ones in which the three consecutive aspartate residues were substituted with alanines, namely D172A, D173A, and D174A, exhibited near-native plasminogen activator activity. Once Pro$^{177}$ was substituted with alanine, at the center of the loop, the resultant mutant also showed an 8- to 10-fold drop in activity. From these results, one can also infer that the proline side chain present in the central region of the loop likely plays a role in maintaining the functionality of this loop, because the deletion or alanine substitution of Pro$^{177}$ perturbed the functionality of the loop. By contrast, proline at position 171 seemed to bear no functional relevance, because the specific activity of P171A mutant was essentially native-like. It is also noteworthy that, although the activation rates decreased to nearly one-tenth of that of wtSK by the lysine to alanine mutation at position 180, the mutation of the residue next to 180 (i.e. D181A) “allowed” the survival of nearly half the HPG activation capability seen with wtSK. This suggests that Lys$^{180}$ has an important role to play in the functioning of the loop, along with Pro residue at position 177. Remarkably, the decrease in $k_{cat}$ seen with these mutants did not result in any significant alteration in apparent substrate affinity (to the extent that can be indicated by $K_m$), which clearly suggests that the functional role of the 170 loop is related to generating substrate processivity in the SK-HPN enzyme complex rather than an overt role in macromolecular substrate binding/docking. These results clearly suggest that the central part, particularly residues in and around position 180, of the 170 loop is important for plasminogen activation.

Various other double- and triple-alanine substitution mutants of the 170 loop were also constructed and examined for their capability to process substrate HPG (Table 1). Interestingly, from the results obtained, it became fairly evident that, although the presence of lysine at position 180 is important in the processing of substrate, other sites in the 170 loop are also contributive to this phenomenon. It can be seen that the mutation K180A, once in combination with other mutations within the 170 loop, such as in the triple substitution mutant, R176A/K180A/D181A, as well as the double substitution mutants, namely R176A/K180A and P177A/K180A, while essentially exhibiting the decline in catalytic turnover rates, still retained a substrate affinity ($K_m$) that was essentially comparable to wild-type SK.

**Probing the Importance of Lysine 180 in the 170 Loop of the β-Domain of Streptokinase**—Because lysine to alanine mutation at position 180 exhibited a markedly reduced ability to activate substrate plasminogen by mutant SK-HPN activator complex, to substantiate our finding we examined whether a positively charged side chain at this position was mandatory for activation of HPG. Accordingly, we prepared different sidechain altered mutants at position 180 and examined their kinetics after complexation with HPG. Interestingly, from the results obtained (Table 1) it is evident that charge reversal mutation at lysine 180, to aspartate, significantly decreased the activation of HPG to levels ~25-fold lower as compared with wtSK (Fig. 3). Glycine substitution at this position also resulted in a drop in specific activity that was roughly comparable to the alanine substitution mutant, but much better than in the case of the Lys to Asp mutation. Interestingly, when the residue was changed to arginine, a rejuvenation of the original activator activity was
activity gets amplified to native-like levels (10). When the full complement of the five kringle domains is present mediates enzyme-substrate interactions that were specifically against HPG as the substrate, in relative terms with respect to observed. Thus, the present study clearly highlights the importance of lysine 180 of the 170 loop of SK in catalytic processing of substrate plasminogen, which is likely due to the requirement of a positive charge at this position. Interestingly, the two amino acid residues identified to be relatively vital for 170 loop functioning, namely Pro177 and Lys180, are phylogenetically conserved across the various streptokinase allelic variant categories (classes) (Fig. 6) despite the generally diverse sequence heterogeneity in this region of streptokinase (34, 35). This suggests the evolutionary significance of these amino acid residues in the 170 loop that impart high catalytic turnover to SK-plasmin.

Selective Interaction of the 170 Loop of Streptokinase with the Catalytic Domain of Plasminogen—To obtain an idea of the broad locale in substrate plasminogen with which the 170 loop interacts, namely the catalytic domain or the kringle domains, a binary interaction of substrate HPG with wtSK was evaluated. The proline to alanine substitution mutant, as well as the double mutant, P177A/K180A, showed a similar magnitude of decline in processing of ␤-PG that is about the same as that exhibited by wtSK, but all of these mutants showed a pronounced decline in their catalytic rates for ␤-PG generation from ␤-PG, compared with the rates seen with wtSK. The same pattern of decline in ␤-PG processing was observed in other alanine mutants of the 170 loop as well. All the alanine substitution mutants exhibited a similar to that seen when HPG was taken as the substrate. The proline to alanine substitution mutant, as well as the double mutant, P177A/K180A, showed a similar magnitude of decline in processing of ␤-PG as that seen with HPG. Overall, these results suggest that the 170 loop of the ␤-domain of streptokinase encompasses a critical site of interaction between the SK-plasminogen complex and the catalytic domain of substrate plasminogen.

Real-time Surface Plasmon Resonance Studies for Ternary-mode Interactions of 170 Loop Mutants with Full-length and Truncated Substrates—The foregoing results for decreased $k_{cat}$ of the various 170 loop mutants for substrate HPG as well as ␤-PG activation prompted us to explore whether the physico-chemically measurable affinity of these substrates with preformed activator complexes between HPG and wtSK, on the one hand, and HPG with various 170 loop mutants, on the other, were affected or not using the real-time surface plasmon resonance technique. For this purpose, varying concentrations of substrate HPG were “docked” onto the preformed binary complex of immobilized HPG, and wtSK/variants 170 loop mutants on the sensor surface, as described earlier (10, 14). The preformed SK-HPG complex has been shown to be relatively refractory to e-aminocaproic acid, whereas the binding of the activator complex with the substrate HPG is susceptible to inhibition in the low millimolar range of concentration (36). The results obtained for the interaction of substrate HPG and ␤-PG are given in Table 3. It is evident from the data that the equilibrium dissociation constants ($K_D$) values for the ternary interaction of substrate HPG were closely similar to that observed earlier (14) in the case of ternary interaction of substrate HPG with native full-length SK (~0.1 $\mu$M; see supplemental materials for binding sensorgrams). It is notable that, despite their lowered catalytic properties, the association and dissociation rate constants for ternary interactions of the 170 loop mutants were found to be closely similar to those observed in the case of ternary interaction of substrate HPG with wtSK.

When the docking of the isolated catalytic domain of plasminogen, i.e. ␤-PG, was performed on the preformed binary complexes of SK/SK 170 loop mutants and HPN, the kinetic parameters for substrate ␤-PG activation were determined at 22 °C with the chromogenic substrate in 50 mM Tris-Cl buffer, pH 7.5, 100 mM NaCl as described under “Experimental Procedures.” The data represent the mean of three independent determinations.

| Activator species | $K_a$ | $k_{cat}$ | $k_{cat}/K_a$ |
|------------------|-------|----------|--------------|
|                  | $\mu$M | $min^{-1}$ | $min^{-1} \mu$M$^{-1}$ |
| wtSK             | 1.2 ± 0.1 | 0.16 ± 0.03 | 0.13 |
| K180A            | 1.2 ± 0.4 | 0.01 ± 0.003 | 0.01 |
| K180G            | 1.5 ± 0.1 | 0.01 ± 0.004 | 0.008 |
| K180R            | 1.2 ± 0.1 | 0.06 ± 0.002 | 0.050 |
| K180D            | 1.0 ± 0.2 | 0.01 ± 0.004 | 0.011 |
| P177A            | 1.2 ± 0.3 | 0.02 ± 0.003 | 0.013 |
| P177A/K180A      | 1.3 ± 0.2 | 0.01 ± 0.003 | 0.009 |

*FIGURE 6.* Multiple alignment of primary sequence of β-domain depicting the 170 loop amino acid residues of streptokinases secreted from *S. equisimilis* and three representative allelic variant clusters of *Streptococcus pyogenes*, namely strains NS210, NS53, NS488, NS696, ALAB49, and NS13 (see Ref. 34). Note that residues (all given in single-letter code) highlighted in bold type are conserved in 170 loop in all the streptokinase polypeptides obtained from the different sources.

TABLE 2

| Activator species | $K_a$ | $k_{cat}$ | $k_{cat}/K_a$ |
|------------------|-------|----------|--------------|
|                  | $\mu$M | $min^{-1}$ | $min^{-1} \mu$M$^{-1}$ |
| wtSK             | 1.2 ± 0.1 | 0.16 ± 0.03 | 0.13 |
| K180A            | 1.2 ± 0.4 | 0.01 ± 0.003 | 0.01 |
| K180G            | 1.5 ± 0.1 | 0.01 ± 0.004 | 0.008 |
| K180R            | 1.2 ± 0.1 | 0.06 ± 0.002 | 0.050 |
| K180D            | 1.0 ± 0.2 | 0.01 ± 0.004 | 0.011 |
| P177A            | 1.2 ± 0.3 | 0.02 ± 0.003 | 0.013 |
| P177A/K180A      | 1.3 ± 0.2 | 0.01 ± 0.003 | 0.009 |
complex of various 170 loop mutants with immobilized HPG, the results demonstrated a native-like equilibrium dissociation constant ($K_D$) of the ternary interaction of substrate $\mu$PG with the three 170 loop mutants chosen for testing (Table 3). However, microplasminogen is known to be a poor substrate for the SK-plasmin(ogen) activator complex (14) with its reported $K_D$ for binding in the ternary mode with the preformed SK-HPG complex being in the range of 1–2 $\mu$M (14). Interestingly, the real-time affinity measurements using surface plasmon resonance analyses for the ternary interaction between $\mu$PG as the substrate and 170 loop mutant complexed with immobilized HPG show equilibrium dissociation constants (~1.0 $\mu$M) that are nearly similar to that of wtSK. These results thus support, on a direct physicochemical level, the observations obtained from the steady-state kinetics studies that the 170 loop, although essential for catalytic processing of substrate plasminogen, does not seem to be contributive substantially toward enzyme-substrate affinity per se.

Even though the present study does not elucidate the exact molecular mechanism by which the 170 loop contributes to catalytic turnover, the observations are suggestive of the fact that the 170 loop interacts specifically with the catalytic domain of substrate. Surprisingly, this interaction does not seem to confer a high degree of enzyme-substrate affinity, because these mutants, after complexation with HPN/HPG, maintain a native-like docking potential for the macromolecular substrates but seem deficient in the post-docking phase of catalysis. These results complement a similar observation regarding the exclusivity of the substrate docking and turnover steps in this enzymatic system, wherein it was shown that the Asp$^{41}$–His$^{48}$ region of SK is involved in binding to substrate plasminogen independent of catalytic efficiency of its active binary complex (37).

The currently favored “exosite” model of SK action (4, 7, 9, 12, 14, 15, 36) envisions an “active valley” in the SK-HPN complex, with the trypsin-like plasmin active center located at its base. The involvement of exosite residues in proteinases of the blood coagulation pathway is well demonstrated in literature (38), an elegant example being that of the thrombinase complex (39, 40), wherein substrate specificity, effector recognition, molecular activation, and regulation of thrombin (41, 42) are modulated by surface exosites unlike, say, a protease such as chymotrypsin, which acts primarily through the active site region (43). It is interesting to note that the role of the 170 loop-located exosite in SK action seems to be solely mediated through effects on the catalytic turnover of the SK-PN enzyme complex. In contrast, the exosite resident in the 250-loop seems to operate also through direct substrate binding (14). It thus appears that SK possesses at least two types of exosites, namely one or more directed to substrate binding and/or product release, especially in the region around the scissile peptide bond in the macromolecular substrate. Thus, it is conceivable that the HPN active center remains essentially as “non-commital” with respect to its primary substrate specificity as is free HPN, but the overall SK-plasmin complex acquires a selective substrate-processing capacity through the stereospecifically guided docking of the macromolecular substrate into this valley. Once this is accomplished, it is logical to assume that facile proteolytic cleavage could now occur at the substrate’s scissile peptide bond, triggering the product expulsion step of catalysis. The exact identity of all exosites participating in this interaction, which also involves long range enzyme-substrate interactions as well (10), is not known currently. Nevertheless, this model is consistent with a mechanistic scenario wherein the 170 loop or, indeed, any other such surface-located, substrate-interacting site(s) on SK, such as the 250-loop or the 88–97 loop (12, 14) act as flexible pivots, or hinges, that facilitate the rapid release of the product from the enzyme at the end of each catalytic cycle even if such an interaction may, or may not (as in case of the 170 loop) necessarily be contributive in terms of enhancing enzyme-substrate affinity. Indeed, one such site, which does contribute toward enzyme-substrate affinity, has already been identified to reside in the fifth kringle of HPG (14, 15). However, the interacting site for the 170 loop in substrate HPN now needs to be identified to closely examine the dynamics of their interaction. Efforts along these lines, using fluorescence resonance energy transfer and cross-linking studies, are currently underway in our laboratory. Besides SK, the role of surface-located loops in plasminogen activation has been strongly indicated in other bacterial and physiological activators as well, such as staphylokinase, tissue plasminogen activator, and urokinase plasminogen activator (44–46), but the exact manner whereby such loops modulate enzymatic specificity and/or catalysis remains to be satisfactorily elucidated. Such an understanding,

---

**TABLE 3**

Association ($k_{in}$) and dissociation ($k_{off}$) rate constants and apparent equilibrium dissociation ($K_D$) constants for the interaction of substrate plasminogen and $\mu$PG with wtSK/170 loop mutants complexed with immobilized HPG by SPR

| Ligand | $k_{in}$ | $k_{off}$ | $K_D$ | $k_{in}$ | $k_{off}$ | $K_D$ |
|--------|---------|-----------|--------|---------|-----------|--------|
| wtSK-HPG | 12 ± 1.5 | 1.8 ± 0.2 | 0.15 ± 0.03 | 1.4 ± 0.5 | 1.5 ± 0.20 | 1.1 ± 0.3 |
| P177A-HPG | 8.0 ± 1.8 | 1.6 ± 0.2 | 0.20 ± 0.04 | 1.5 ± 0.3 | 1.7 ± 0.15 | 1.1 ± 0.2 |
| K180A-HPG | 11 ± 2.0 | 1.5 ± 0.3 | 0.14 ± 0.02 | 1.1 ± 0.3 | 1.4 ± 0.15 | 1.2 ± 0.2 |
| K180D-HPG | 12.5 ± 2.0 | 1.5 ± 0.4 | 0.12 ± 0.02 | 1.2 ± 0.2 | 1.2 ± 0.15 | 1.0 ± 0.2 |
Mechanism of Streptokinase Action

undoubtedly, will be helpful in the redesign of existing plasminogen activators, and perhaps, also in the de novo design of proteases with new substrate specificities. In our current working model of SK action, it is the co-operative action of the various exosites that leads to the generation of high rates of plasminogen activation by SK, which is known to be highest among all other physiological and bacterial PG activators (47). Our preliminary observations with simultaneous multisite mutations in the various exosites of SK identified so far, on the one hand, and sites in the macromolecular substrate that are appreciably distant from the scissile peptide bond, on the other, reveal highly synergistic effects on the catalytic rates for HPG activators, and perhaps, also in the de novo network of exosites in the SK mechanism that is centered on the existence of a “distributed” network of exosites in the SK-HPN enzymatic complex.

Acknowledgments—We thank Paramjit Kaur and Deepak Bhatt for expert technical support, and the Blood Bank, Government Medical College, Chandigarh for human plasma.

REFERENCES

1. Lijnen, H. R., Stassen, I. M., Vanninboudh, L., Fukao, H., Okada, K., Matsuoka, O., and Collen, D. (1991) *Thromb. Haemost.* 66, 468–473
2. McClintock, D. K., and Bell, P. H. (1971) *Biochem. Biophys. Res. Commun.* 43, 694–702
3. Bajaj, A. P., and Castellino, F. J. (1977) *J. Biol. Chem.* 252, 492–498
4. Boxrud, P. D., Verhamme, I. M., and Bock, P. E. (2004) *J. Biol. Chem.* 279, 36633–36641
5. Boxrud, P. D., and Bock, P. E. (2009) *J. Biol. Chem.* 284, 10266–10271
6. Boxrud, P. D., Verhamme, I. M., Fay, W. P., and Bock, P. E. (2000) *J. Biol. Chem.* 275, 14579–14589
7. Reddy, K. N., and Markus, G. (1972) *J. Biol. Chem.* 247, 1683–1691
8. Wang, X., Lin, X., Loy, J. A., Tang, J., and Zhang, X. C. (1998) *Science* 281, 1662–1665
9. Wang, X., Lin, X., Loy, J. A., Tang, J., and Zhang, X. C. (1998) *J. Biol. Chem.* 273, 30569–30577
10. Chaudhary, A., Vasudha, S., Rajagopal, K., Komath, S. S., Garg, N., Yadav, M., Mande, S. C., and Sahni, G. (1999) *Protein Sci.* 8, 2791–2805
11. Chaudhary, A., Vasudha, S., Rajagopal, K., Komath, S. S., Garg, N., Yadav, M., Mande, S. C., and Sahni, G. (1999) *Protein Sci.* 8, 2791–2805
12. Yadav, S., Datt, M., Singh, B., and Sahni, G. (2008) *Biochim. Biophys. Acta.* 1784, 1310–1318
13. Reed, G. L., Lin, L. F., Parmami-Seren, B., and Kussie, P. (1995) *Biochemistry* 34, 10266–10271
14. Reed, G. L., Lin, L. F., Parmami-Seren, B., and Kussie, P. (1995) *Biochemistry* 34, 10266–10271
15. Tharp, A. C., Laha, M., Panizzi, P., Thompson, M. W., Fuentes-Prior, P., and Bock, P. E. (2009) *J. Biol. Chem.* 284, 19511–19521
16. Wang, X., Tang, J., Hunter, B., and Zhang, X. C. (1999) *FERS Lett.* 459, 85–89
17. Deutsch, D. G., and Mertz, E. T. (1970) *Science* 170, 1095–1096
18. Shi, G. Y., and Wu, H. L. (1988) *J. Biol. Chem.* 263, 17071–17075
19. Wang, S., Reed, G. L., and Hedstrom, L. (1999) *Biochemistry* 38, 5232–5240
20. Radek, J. T., Davidson, D. J., and Castellino, F. J. (1993) *Methods Enzymol.* 223, 145–155
21. Wohl, R. C., Summario, L., and Robbins, K. C. (1980) *J. Biol. Chem.* 255, 2005–2013
22. Wakeham, N., Terzyan, S., Zhai, P., Loy, J. A., Tang, J., and Zhang, X. C. (2002) *Protein Eng.* 15, 753–761
23. Chace, T., Jr., and Shaw, E. (1969) *Biochemistry* 8, 2212–2224
24. Wohl, R. C. (1984) *Biochemistry* 23, 3799–3804
25. Jackson, K. W., and Tang, J. (1982) *Biochemistry* 21, 6620–6625
26. Wohl, R. C., and Reed, G. L. (1982) *Eur. J. Biochem.* 213, 1310–1318
27. Wohl, R. C., Reed, G. L., and Sahni, G. (1998) *Science* 279, 637–648
28. De Renzo, E. C., Suteri, P. K., Hutchings, B. L., and Bell, P. H. (1967) *J. Biol. Chem.* 242, 533–542
29. Wang, X., Reed, G. L., and Hedstrom, L. (2000) *Eur. J. Biochem.* 267, 3994–4001
30. Boxrud, P. D., Verhamme, I. M., Fay, W. P., and Bock, P. E. (2001) *J. Biol. Chem.* 276, 26084–26089
31. Harel, P. H., Schmitter, M. J., Dessen, P., Fayat, G., and Blanquet, S. (1989) *Proc. Natl. Acad. Sci. U.S.A.* 86, 8247–8251
32. Summario, L., Wohl, R. C., Boreisha, I. G., and Robbins, K. C. (1982) *Biochemistry* 21, 2056–2059
33. Gonzalez-Gronow, M., Siefring, G. E., Jr., and Castellino, F. J. (1978) *J. Biol. Chem.* 253, 1090–1094
34. Lizardo, S., and Johnston, K. H. (2005) *Infect. Immun.* 73, 4451–4453
35. McArthur, J. D., McKay, F. C., Ramachandran, V., Shyam, P., Cork, A. J., Sanderson-Smith, M. L., Cole, J. N., Ringtahl, U., Sjobring, U., Ransow, H., and Walker, M. J. (2008) *FASEB J.* 22, 3146–3153
36. Lin, L. F., Houng, A., and Reed, G. L. (2000) *Biochemistry* 39, 4740–4745
37. Kim, D. M., Lee, S. J., Kim, I. C., Kim, S. T., and Byun, S. M. (2000) *Thromb. Res.* 99, 93–98
38. Bock, P. E., Panizzi, P., and Verhamme, I. M. (2007) *Thromb. Haemost.* 98, Suppl. 1, 81–94
39. Boskovic, D. S., and Krishnaswamy, S. (2000) *J. Biol. Chem.* 275, 38561–38570
40. Krishnaswamy, S. (2005) *J. Thromb. Haemost.* 3, 54–67
41. Huntington, J. A. (2005) *J. Thromb. Haemost.* 3, 1861–1872
42. Bode, W. (2006) *Blood Cells Mol. Dis.* 36, 122–130
43. Furie, B., Bing, D. H., Feldmann, R. J., Robison, D. J., Burnier, J. P., and Furie, B. C. (1982) *J. Biol. Chem.* 257, 3875–3882
44. Rajamohan, G., Dahya, M., Mande, S. C., and Dikshit, K. L. (2002) *Biochem. J.* 365, 379–389
45. Tachias, K., and Madison, E. L. (1996) *J. Biol. Chem.* 271, 28749–28752
46. Petersen, H. H., Hansen, M., Schousboe, S. L., and Andreassen, P. A. (2001) *Eur. J. Biochem.* 268, 4430–4439
47. Lee, P. P., Wohl, R. C., Boreisha, I. G., and Robbins, K. C. (1988) *Biochemistry* 27, 7506–7513

3 R. Aneja, S. Yadav, K. Joshi, S. Kumar, and G. Sahni, unpublished observations.